Literature DB >> 1280410

Fontan procedure for hypoplastic left heart syndrome.

W I Norwood1, M L Jacobs, J D Murphy.   

Abstract

Since 1985, 354 neonates have undergone palliative reconstruction for hypoplastic left heart syndrome with 109 early deaths and 12 late deaths. Of the survivors, before 1989, 77 patients underwent a subsequent modified Fontan operation, consisting of baffling the atrial septal defect to the tricuspid valve (initial 25 patients) or intraatrial baffling of the inferior vena cava to the pulmonary arteries and superior vena cava (52 patients). There were 17 early deaths and three late deaths. Major serous effusions developed in 42 patients (54%) after Fontan operation. Since 1989, a staged approach to Fontan's operation was undertaken in an effort to reduce the volume load of the right ventricle as early as possible, to minimize the impact of rapid changes in ventricular geometry and diastolic function that can accompany a primary Fontan operation, and to reduce effusive complications. Thus, at a mean age of 6 months, 121 patients have undergone closure of aortopulmonary shunt, augmentation of central pulmonary arteries, and association of the superior vena cava with the branch pulmonary arteries (hemi-Fontan procedure). Of these, 61 patients have already undergone completion of the Fontan procedure with six early deaths and three late deaths. Major serous effusions developed in 28 patients (46%) with the staged Fontan. For perspective, the contemporary experience since January 1991 consists of 58 neonates who have undergone initial palliation with 11 deaths (19%), 17 patients who have undergone the hemi-Fontan procedure with one death (6%), and 21 patients who have undergone completion of the Fontan operation with one death (5%).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1992        PMID: 1280410     DOI: 10.1016/0003-4975(92)90065-c

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  9 in total

1.  [Norwood procedure to hypoplastic left heart syndrome].

Authors:  S Sano; M Kawada; H Yoshida; K Kino; H Irie; A Aoki; H Mitani; K Nakamura; M Inoue
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-12

Review 2.  Extracardiac conduit Fontan procedure versus intra-atrial lateral tunnel Fontan procedure.

Authors:  Toshiyuki Katogi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-10-18

3.  Surgical treatment for hypoplastic left heart syndrome.

Authors:  E L Bove
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1999-02

Review 4.  Anesthetic management of noncardiac surgery for patients with single ventricle physiology.

Authors:  Koichi Yuki; Alfonso Casta; Shoichi Uezono
Journal:  J Anesth       Date:  2011-01-01       Impact factor: 2.078

5.  Simulations reveal adverse hemodynamics in patients with multiple systemic to pulmonary shunts.

Authors:  Mahdi Esmaily-Moghadam; Bari Murtuza; Tain-Yen Hsia; Alison Marsden
Journal:  J Biomech Eng       Date:  2015-01-29       Impact factor: 2.097

6.  Management and outcome of infants and children with right atrial isomerism.

Authors:  M Sadiq; O Stümper; J V De Giovanni; J G Wright; B Sethia; W J Brawn; E D Silove
Journal:  Heart       Date:  1996-03       Impact factor: 5.994

7.  Surgery for infants with a hypoplastic systemic ventricle and severe outflow obstruction: early results with a modified Norwood procedure.

Authors:  F A Bu'Lock; O Stümper; R Jagtap; E D Silove; J V De Giovanni; J G Wright; B Sethia; W J Brawn
Journal:  Br Heart J       Date:  1995-05

8.  Staged reconstruction for hypoplastic left heart syndrome. Contemporary results.

Authors:  E L Bove; T R Lloyd
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

9.  Total cavopulmonary connection with a new restorative vascular graft: results at 2 years.

Authors:  Leo Bockeria; Thierry Carrel; Anais Lemaire; Vladimir Makarenko; Alex Kim; Konstantin Shatalov; Martijn Cox; Oleg Svanidze
Journal:  J Thorac Dis       Date:  2020-08       Impact factor: 2.895

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.